CRVO News & Events

CervoMed announced that it has entered into definitive agreements for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about June 22, 2026, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the company from the offering are expected to be $10M, before deducting placement agent fees and other offering expenses payable by the company. The company intends to use the net proceeds from the offering for working capital and general corporate purposes.

CervoMed announced that it has received a notice of allowance from the United States Patent and Trademark Office, USPTO, related to a new patent protecting the Company's use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies in patients with no substantial Alzheimer's disease-like tau pathology, also known as "pure DLB". The patent will cover the treatment of DLB without substantial tau pathology, which can be characterized by plasma levels of pTau or brain imaging, and is expected to provide intellectual property protection into 2042 and potentially longer with patent term extension. The patent is designed to protect the Company's strategy targeting the treatment of patients with pure DLB. Currently, there are no approved treatments for DLB in the United States or European Union.